Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy

Technology appraisal guidance
Reference number: TA736
Published: 20 October 2021

History

Expected publication

Equality Impact Assessment (Guidance development) (PDF 140 KB)

Published:

20 October 2021

Final draft guidance: TA736

Final draft guidance: TA736
Final appraisal document (PDF 305 KB)

Published:

15 September 2021
Committee papers (PDF 1.9 MB)

Published:

15 September 2021
Public committee slides (PDF 776 KB)

Published:

15 September 2021

Draft guidance: TA736

Draft guidance: TA736
Appraisal consultation document (online commenting)
Appraisal consultation document (PDF version) (PDF 292 KB)

Published:

07 January 2021
Public committee slides (PDF 274 KB)

Published:

07 January 2021
Committee papers (PDF 3.58 MB)

Published:

07 January 2021

Invitation to participate

Final scope (PDF 157 KB)

Published:

30 January 2020
Final stakeholder list (PDF 187 KB)

Published:

30 January 2020

Final draft guidance: TA490

Committee papers TA490 (PDF 4.28 MB)

Published:

20 July 2023
Final appraisal document TA490 (PDF 454 KB)

Published:

20 July 2023

Draft guidance: TA490

Committee papers TA490 (PDF 13.25 MB)

Published:

20 July 2023
Appraisal consultation document (PDF version) TA490 (PDF 514 KB)

Published:

20 July 2023